Mapping ICD-10 and ICD-10-CM Codes to Phecodes::Workflow Development and Initial Evaluation by Wu, Patrick et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mapping ICD-10 and ICD-10-CM Codes to Phecodes:
Citation for published version:
Wu, P, Gifford, A, Meng, X, Li, X, Campbell, H, Varley, T, Zhao, J, Carroll, R, Bastarache, L, Denny, JC,
Theodoratou, E & Wei, W-Q 2019, 'Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow
Development and Initial Evaluation', JMIR Medical Informatics , vol. 7, no. 4. https://doi.org/10.2196/14325
Digital Object Identifier (DOI):
10.2196/14325
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
JMIR Medical Informatics
Publisher Rights Statement:
This is the author’s peer-reviewed manuscript as accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
 1 
Original Paper 
Patrick Wu, BS1,5,a, Aliya Gifford, PhD1,a, Xiangrui Meng, PhD2,a, Xue Li, PhD2, Harry 
Campbell, MD2, Tim Varley, BSc3, Juan Zhao, PhD1, Robert Carroll, PhD1, Lisa 
Bastarache, MS1, Joshua C Denny, MD MS1,6, Evropi Theodoratou, PhD2,4, Wei-Qi Wei, 
MD PhD1 
  
1Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, 
TN, USA 
2Centre for Global Health Research, Usher Institute of Population Health Sciences and 
Informatics, The University of Edinburgh, Edinburgh, UK 
3Public Health and Intelligence SBU, National Services Scotland, Edinburgh, UK 
4Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The 
University of Edinburgh, Edinburgh, UK 
5Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, 
TN, USA 
6Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA 
  
aAuthors made equal contributions to the paper 
  
Correspondence to:    
Wei-Qi Wei, MD PhD 
Email:  wei-qi.wei@vumc.org 
Department of Biomedical Informatics 
Vanderbilt University Medical Center 
2525 West End Ave., Suite 1500 
Nashville, TN 37203 
Tel: (615) 343-1956 
Fax: (615) 936-0102 
  
Developing and Evaluating Mappings of ICD-10 and ICD-10-
CM Codes to Phecodes 
  
Abstract 
Background:  
The phecode system was built upon the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) for phenome-wide association studies 
(PheWAS) in the electronic health record (EHR).  
Objectives:  
We present our work on the development and evaluation of maps from ICD-10 and ICD-
10-CM codes to phecodes.  
Methods: 
We mapped ICD-10 and ICD-10-CM codes to phecodes using a number of methods 
and resources, such as concept relationships and explicit mappings from the Centers 
for Medicare & Medicaid Services, the Unified Medical Language System, 
Observational Health Data Sciences and Informatics, Systematized Nomenclature of 
Medicine - Clinical Terms, and the National Library of Medicine. We assessed the 
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coverage of the maps in two databases: Vanderbilt University Medical Center (VUMC) 
using ICD-10-CM and the UK Biobank (UKBB) using ICD-10. We assessed the fidelity 
of the ICD-10-CM map in comparison to the gold-standard ICD-9-CM phecode map by 
investigating phenotype reproducibility and conducting a PheWAS. 
Results: 
We mapped >75% of ICD-10 and ICD-10-CM codes to phecodes. Of the unique codes 
observed in the UKBB (ICD-10) and VUMC (ICD-10-CM) cohorts, >90% were mapped 
to phecodes. We observed 70-75% reproducibility for chronic diseases and <10% for an 
acute disease for phenotypes sourced from the ICD-10-CM phecode map. Using the 
ICD-9-CM and ICD-10-CM maps, we conducted a PheWAS with a lipoprotein(a) (LPA) 
genetic variant, rs10455872, which replicated two known genotype-phenotype 
associations with similar effect sizes: coronary atherosclerosis (ICD-9-CM: P=1.96E-15, 
odds ratio (OR) = 1.60, 95% confidence interval (CI): 1.43-1.80  vs. ICD-10-CM: 
P=8.63E-16, OR = 1.60, 95% CI: 1.43-1.80) and chronic ischemic heart disease (ICD-9-
CM: P=4.18E-10, OR = 1.56, 95% CI: 1.35-1.79  vs. ICD-10-CM: P=5.21E-05, OR = 
1.47, 95% CI: 1.22-1.77). 
Conclusions:  
This study introduces the “beta” versions of ICD-10 and ICD-10-CM to phecode maps 
that enable researchers to leverage accumulated ICD-10 and ICD-10-CM data for 
PheWAS in the EHR. The maps are available from https://phewascatalog.org and 
incorporated in the PheWAS R package, https://github.com/PheWAS/PheWAS. 
  
Keywords: 
electronic health record; genome-wide association study; phenome-wide association 
study; phenotyping 
  
Introduction 
  
Background 
Electronic health records (EHRs) have become a powerful resource for biomedical 
research in the last decade, and many studies based on EHR data have used 
International Classification of Diseases (ICD) codes [1]. When linked to DNA biobanks, 
healthcare information in EHRs is a tool to discover genetic associations using billing 
codes in phenotyping algorithms. The phenome-wide association study (PheWAS) 
paradigm was introduced in 2010 as an approach that scans across a range of 
phenotypes, similar to genome-wide association studies. Studies using PheWAS have 
replicated hundreds of known genotype-phenotype associations and discovered dozens 
of new ones [2–12]. The initial version of phecodes consisted of 733 custom groups of 
ICD Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes. The most recent 
iteration of phecodes consists of 1,866 hierarchical phenotype codes that map to 15,558 
ICD-9-CM codes [13,14]. However, many health systems and international groups use 
ICD-10 or ICD-10-CM codes [15], therefore necessitating a new phecode map. 
  
Transition from ICD-9 to ICD-10 
In 1979, the World Health Organization (WHO) developed ICD-9 to track mortality and 
morbidity. To improve its application to clinical billing, the United States National Center 
 3 
for Health Statistics (NCHS) modified ICD-9 codes to create ICD-9-CM, whose end-of-
life date was scheduled around the year 2000, but was delayed until October 2015 [15]. 
In 1990, the WHO developed ICD-10 [16], which the NCHS used to create ICD-10-CM 
to replace ICD-9-CM.  
  
Moving from ICD-9-CM to ICD-10-CM led to major structural changes in the coding 
system. First, the structure moved from a broadly numeric-based system in ICD-9-CM 
(e.g. 474.11 for “Hypertrophy of tonsils alone”) to an alphanumeric system in ICD-10-
CM (e.g. J35.1 for the same condition). Second, ICD-10-CM contains much more 
granular information than ICD-9-CM, as seen with the approximately tenfold increase in 
the number of diabetes-related codes in ICD-10-CM. ICD-10-CM also differs from ICD-
9-CM in terms of semantics and organization [15,17]. 
  
Compared to ICD-10, ICD-10-CM has more codes and granularity. While the 2018AA 
Unified Medical Language System (UMLS) [18] contains 94,201 unique ICD-10-CM 
codes, it has 12,027 unique ICD-10 codes after exclusion of range codes (e.g. ICD-10-
CM A00-A09). Further, there are ICD-10 codes that do not exist in ICD-10-CM, and vice 
versa, such as ICD-10 A16.9 “Respiratory tuberculosis unspecified, without mention of 
bacteriological or histological confirmation”, which has no ICD-10-CM equivalent.  
  
Prior Work 
To develop the original phecode system, one or more related ICD-9-CM codes were 
combined into distinct diseases or traits. For example, three depression-related ICD-9-
CM codes 311, 296.31, and 296.2 are condensed to phecode 296.2 “Depression”. With 
the help of clinical experts in disparate domains, such as cardiology and oncology, we 
have iteratively updated the phecode groupings [19]. 
  
The phecode scheme is unique because it has built-in exclusion criteria to prevent 
contamination by cases in the control cohort. This is an important feature, as case 
contamination of control groups decreases the statistical power to find genotype-
phenotype associations [20]. For each disease phenotype, we defined exclusion criteria 
by using our clinical knowledge and by consulting physician specialists.  
  
An example for how users can use phecode exclusion criteria is illustrated by a type 2 
diabetes study in the EHR. To define cases of type 2 diabetes, users include patients 
with ICD codes that map to phecode 250.2 “Type 2 diabetes”. To create the control 
cohort, they include patients without phenotypes in the “DIABETES” group, which is 
comprised of phecodes in the range of 249-250.99. This prevents contamination of the 
control group by patients with diseases such as “Type 1 diabetes” (phecode 250.1) and 
“Secondary diabetes mellitus” (phecode 249). Excluded patients also include those with 
signs and symptoms commonly associated with type 2 diabetes, such as “Abnormal 
glucose” (phecode 250.4), which may indicate someone who has not yet been 
diagnosed with diabetes. 
  
Though the phecode system is effective at replicating and identifying novel genotype-
phenotype associations, PheWAS have largely been limited to using ICD-9-CM codes. 
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A few studies have mapped ICD-10 codes to phecodes by converting ICD-10 to ICD-9-
CM, and then mapping the converted ICD-9-CM codes to phecodes [3,10]. However, 
these studies limited their mappings to ICD-10 (non-CM) codes, did not provide a map 
to translate ICD-10-CM codes to phecodes, and did not evaluate the accuracy of these 
maps.  
  
Goal of this Study 
In this study, we developed and evaluated maps of ICD-10 and ICD-10-CM codes to 
phecodes. The primary aims of this study were to create an initial “beta” map to perform 
PheWAS using ICD-10 and ICD-10-CM codes and to focus the analyses on PheWAS-
relevant codes. Our goal was to demonstrate that researchers should expect similar 
results from the ICD-10-CM phecode map compared to the gold-standard ICD-9-CM 
map. To accomplish this goal, we investigated phecode coverage, phenotype 
reproducibility, and the results from a PheWAS.  
 
Methods 
 
Databases 
In this study, we used data obtained from the Vanderbilt University Medical Center 
(VUMC) and UK Biobank (UKBB) [25] databases. The VUMC EHR contains clinical 
information derived from the medical records of >3 million unique individuals. The UKBB 
is a prospective longitudinal cohort study designed to investigate the genetic and 
environmental determinants of diseases in UK adults. Between 2006-2010, the study 
recruited >500,000 men and women aged 40-69 years. Participants consented to allow 
their data to be linked to their medical records. EHR records of UKBB were obtained 
under an approved data request application (ID:10775). 
  
At the time of this study, VUMC had >2.5 years of ICD-10-CM data (~2015-10-01 to 
2017-06-01), while the UKBB had >2 decades of ICD-10 data [21] (~1995-04-01 to 
2015-03-31). VUMC includes codes for inpatient and outpatient encounters, whereas 
UKBB codes in this study are only inpatient codes. 
  
Mapping ICD-10-CM and ICD-10 Codes to Phecodes 
We extracted ICD-10-CM codes from the 2018AA release of the UMLS [18], and used a 
number of automated methods to translate ICD-10-CM diagnosis codes to phecodes 
(Figure 1). We mapped 515 ICD-10-CM codes directly to phecodes by matching code 
descriptions regardless of capitalization, e.g. ICD-10-CM H52.4 “Presbyopia” to 
phecode 367.4 “Presbyopia”. We mapped 82,287 ICD-10-CM codes indirectly to 
phecodes using the existing ICD-9-CM phecode map [14]. To convert ICD-10-CM codes 
indirectly to phecodes, we used General Equivalence Mappings (GEMS) provided by 
the Centers for Medicare & Medicaid Services, that maps ICD-10-CM to ICD-9-CM and 
vice versa [22]. We included both equivalent and non-equivalent GEMS mappings (i.e. 
where the "approximate" flag was either "0" or "1"). As an example of this indirect 
approach, to map ICD-10-CM E11.9 “Type 2 diabetes mellitus without complications” to 
phecode 250.2 “Type 2 diabetes”: ICD-10-CM E11.9 to ICD-9-CM 250.0 “Diabetes 
mellitus without mention of complication” to phecode 250.2.  
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Since the GEMS do not provide mappings for all ICD-10-CM codes [17], we 
complemented this approach with UMLS semantic mapping [23], Observational Health 
Data Sciences and Informatics (OHDSI) concept relationships [24,25], and National 
Library of Medicine (NLM) maps [26]. In this approach to indirect mapping, we first 
mapped ICD-10-CM codes to Systematized Nomenclature of Medicine Clinical Terms 
(SNOMED CT) through UMLS Concept (CUI) equivalents, which were then converted to 
ICD-9-CM through either UMLS CUI equivalents [18,23], OHDSI [24], or NLM maps [26]. 
For example, ICD-10-CM L01.00 “Impetigo, unspecified” to CUI C0021099 to SNOMED 
CT 48277006 to OHDSI Concept ID 140480 to OHDSI Concept ID 44832600 to ICD-9-
CM 684 to phecode 686.2 “Impetigo”. 
  
  
 
Figure 1. Mapping strategy for ICD-10 (non-CM) and ICD-10-CM diagnosis codes to 
phecodes. We mapped ICD-10-CM codes directly by matching code descriptions (path 
A) or indirectly to phecodes, using a number of manually-validated mapping resources 
(paths B, C, D, E, and F). In path D, we used NLM’s SNOMED CT to ICD-9-CM one-to-
one and many-to-one maps [26]. To map ICD-9-CM codes to phecodes, we applied 
Phecode Map 1.2 with ICD-9 Codes (ICD-9-CM phecode map) [14]. Boxes with solid 
lines indicate clinical terminologies, and those with dashed lines describe the resources 
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and mapping methods used. ICD-10-CM: International Classification of Diseases, Tenth 
Revision, Clinical Modification. SNOMED CT: Systematized Nomenclature of Medicine 
Clinical Terms. GEMS: General Equivalence Mappings. UMLS: Unified Medical 
Language System. OHDSI: Observational Health Data Sciences and Informatics. CUI: 
Concept Unique Identifier. NLM: National Library of Medicine. 
  
  
There were two general instances when an ICD-10-CM code mapped to more than one 
phecode. First, some ICD-10-CM codes mapped to a parent phecode and one if its child 
phecodes that was lower in the hierarchy. To maintain the granular meanings of ICD-
10-CM codes, we only kept the mappings to child phecodes, a decision that we could 
make due to the hierarchical structure of phecodes. For example, ICD-10-CM I10 
“Essential (primary) hypertension” was mapped to phecodes 401 “Hypertension” and 
401.1 “Essential hypertension”, but we only kept the mapping to phecode 401.1. 
Second, we kept all the mappings for ICD-10-CM codes that were translated to 
phecodes that were not in the same family. This can be seen in the mapping of ICD-10-
CM D57.812 “Other sickle-cell disorders with splenic sequestration” to phecodes 282.5 
“Sickle cell anemia” and 289.5 “Diseases of spleen”. This latter association created a 
polyhierarchical nature to phecodes that did not previously exist.         
 
To map ICD-10 (non-CM) codes to phecodes, we used ICD-10 codes also from the 
2018AA UMLS [18]. ICD-10 codes were mapped to phecodes in a similar manner to 
ICD-10-CM, but since a GEMS to translate ICD-10 to ICD-9-CM was not available, we 
used only string matching and previously manually-reviewed resources from the UMLS 
[23], NLM [26], and OHDSI [24,25]. 
 
Evaluation of Phecode Coverage of ICD-10 and ICD-10-CM in UKBB and VUMC 
To evaluate the phecode coverage of ICD-10 and ICD-10-CM source codes in UKBB 
and VUMC, respectively, we calculated the number of source codes in the 2018AA 
UMLS, number of source codes mapped to phecodes, and number of mapped and 
unmapped source codes that were used in the two EHRs (Figure 2). To identify 
potential limitations of our automated mapping approach, two authors with clinical 
training (P.W., W.Q.W.) manually reviewed all the unmapped ICD-10 and ICD-10-CM 
codes that were used at UKBB and VUMC, respectively. 
 
Comparison of Phenotypes Generated from the ICD-10-CM Phecode Map  
We aimed to provide evidence that the ICD-10-CM phecode map resulted in 
phenotypes similar to those sourced from the ICD-9-CM phecode map. First, we 
selected 357,728 patients in the VUMC EHR who had ≥1 ICD-9-CM and ≥1 ICD-10-CM  
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Figure 2.  Counts of distinct ICD-10-CM source codes at VUMC and ICD-10 (non-CM) 
source codes in UKBB. (A) Number of unique ICD-10-CM codes in each category. For 
example, there were 34,793 unique codes (grey section) that were in the official ICD-10-
CM system, observed in the VUMC dataset, and mapped to phecodes. (B) Number of 
unique ICD-10 codes in each category. For example, there were 5,823 unique codes 
(off-white section) that were in the official ICD-10 system, observed in the UKBB dataset, 
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and mapped to phecodes. VUMC: Vanderbilt University Medical Center. UKBB: UK 
Biobank. 
 
codes in two 18-month windows. We selected windows to occur prior to and after 
VUMC’s transition to ICD-10-CM. To reduce potential confounders, we left a six-month 
buffer after ICD-9-CM was replaced with ICD-10-CM. Further, the ICD-10-CM 
observation window ended before VUMC switched from its locally developed EHR [27] 
to the Epic system. This created two windows ranging from 2014-01-01 to 2015-06-30 
for ICD-9-CM, and 2016-01-01 to 2017-06-30 for ICD-10-CM (Figure 3). The final cohort 
consisted of 55.10% female with mean (standard deviation, SD) 45 (25) years old. From 
the two observation periods, we extracted all ICD-9-CM and ICD-10-CM codes for each 
patient. We then mapped these codes to phecodes using the ICD-9-CM phecode [14] 
and ICD-10-CM phecode maps.   
 
 
 
Figure 3. Timeline of the two 18-month periods from which ICD-9-CM and ICD-10-CM 
codes from VUMC were analyzed. The cohort of 357,728 patients had at least one ICD-
9-CM and one ICD-10-CM code in the respective 18-month windows.  
 
We used the patient cohort to test our hypothesis that the ICD-10-CM phecode map 
created phenotype definitions that were comparable to those generated using the gold-
standard ICD-9-CM phecode map. For this analysis, we used four common chronic 
diseases (Hypertension, Hyperlipidemia, Type 1 Diabetes, and Type 2 Diabetes) and 
chose one acute disease (Intestinal infection) as a negative control. We expected that a 
large majority of the chronic disease patients and small minority of the acute disease 
patients from the ICD-9-CM era would reproduce the same phenotypes during the ICD-
10-CM era. We defined the phenotype cases as follows: Hypertension with phecodes 
401.* ( “*” means one or more digits or a period); Hyperlipidemia, phecodes 272.*; Type 
1 diabetes, phecodes 250.1*; Type 2 diabetes, phecodes 250.2*; Intestinal infection, 
phecodes 008.*. 
 
For each phenotype, we reported the number of ICD-9-CM cases and the number of 
those individuals who were also ICD-10-CM cases. To identify the possible reasons for 
individuals who were not identified as phenotype cases in the ICD-10-CM period, two 
authors with clinical training (P.W., W.Q.W.) manually reviewed the EHRs of ten 
randomly selected patients from each chronic disease group, except Type 1 diabetes, 
for a total of thirty patients. 
 
 9 
Comparative PheWAS Analysis of Lipoprotein(a) (LPA) Single-nucleotide 
polymorphism (SNP) 
To evaluate the accuracy of the ICD-10-CM phecode map, we performed two PheWAS 
on an LPA genetic variant (rs10455872) using mapped phecodes from ICD-9-CM and 
ICD-10-CM. The LPA SNP is associated with increased risks of developing 
hyperlipidemia and cardiovascular diseases [28–30]. 
 
We used data from BioVU, the de-identified DNA biobank at VUMC to conduct the 
PheWAS [31]. We identified 13,900 adults (56.90 % female, 59 (15) years old in 2014), 
who had rs10455872 genotyped, and at least one ICD-9-CM and ICD-10-CM code in 
their respective time windows. For rs10455872, we observed 86.7% AA, 12.8% AG, and 
0.5% GG. We used 1,632 phecodes that overlapped in the time windows for PheWAS 
using the R PheWAS package [13] with binary logistic regression, adjusting for age, sex, 
and race. 
 
Results 
 
Phecode Coverage of ICD-10-CM and ICD-10 in VUMC and UKBB 
Of all possible ICD-10-CM codes [32], 82,303 (87.37%) mapped to at least one 
phecode, with 7,881 (8.37%) mapping to >1 phecode. For example, ICD-10-CM I25.708 
“Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of 
angina pectoris” mapped to phecodes 411.3 “Angina pectoris” and 411.4 “Coronary 
atherosclerosis”. Of all possible ICD-10 codes, 9,060 (75.33%) mapped to at least one 
phecode, and 289 (2.40%) mapped to >1 phecode. For example, ICD-10 code B21.1 
“HIV disease resulting in Burkitt lymphoma” maps to phecodes 071.1 “HIV infection, 
symptomatic” and 202.2 “Non-Hodgkins lymphoma”. 
 
Among the 36,858 ICD-10-CM codes used at VUMC, 34,793 (94.40%) codes were 
mapped to phecodes. In the UKBB, 5,823 (93.24%) of the ICD-10 codes mapped to 
phecodes (Table 1, Figure 2). Considering all the instances of ICD-10-CM and ICD-10 
codes used at each site, we generated a total count of unique codes grouped by patient 
and date, and those codes that mapped to phecodes (Table 1). Among the total number 
of codes used, 89.72% of ICD-10-CM and 83.68% of ICD-10 codes were mapped to 
phecodes.  
 
Table 1. ICD-10-CM and ICD-10 codes data summary. 
 ICD-10-CM (No.) 
(VUMC) 
ICD-10 (No.) 
(UKBB) 
Official classification systems   
Unique codes 94,201 12,027 
Unique codes mapped 82,303 (87.37%) 9,060 (75.33%) 
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Official codes used in cohorts   
Unique codes   36,858 6,245 
Unique codes mapped 34,793 (94.40%) 5,823 (93.24%) 
Total patients (with ICD-10-CM or ICD-10 
codes) 651,649 391,181 
Total instances of all ICD codes 19,682,697 5,114,363 
Instances mapped to phecodes  17,658,470 (89.72%) 
4,279,544 
(83.68%) 
 
Analysis of Unmapped ICD-10 and ICD-10-CM Codes 
Majority of the unmapped ICD-10 codes used in the UKBB dataset represented medical 
concepts related to personal (i.e. past medical history) or family history of disease. For 
ICD-10-CM, removing codes used at VUMC that we expected to be unmapped (i.e. 
local or supplementary classification codes) left 2,065 ICD-10-CM codes that did not 
map to a phecode. After excluding X, Y, and Z codes (1,395 codes), 670 codes 
remained, majority of which represented either “external causes of morbidity” or “factors 
influencing health status and contact with health services”. All of the remaining 
unmapped ICD-10-CM codes in this cohort had <200 unique individuals (i.e. <.1% of the 
cohort), and majority of the ICD-10-CM codes with >10 unique individuals were 
phenotypes that are most likely due to non-genetic factors. For example, 287 (59.2%) of 
the unmapped ICD-10-CM codes represented external causes of morbidity, such as 
assault and injuries due to motor vehicle accidents. 
 
Reproducibility Analysis of the ICD-10-CM Phecode map 
In the defined 18-month time windows, a cohort 357,728 patients had both ICD-9-CM 
and ICD-10-CM codes (Figure 3). For the chronic diseases, 70-75% of individuals with 
the relevant phecodes in the ICD-9-CM observation period also had the same phecodes 
of interest during the ICD-10-CM period. On the contrary, for the reproducibility analysis 
with an acute disease, we observed that <10% of individuals who had phecodes 008.* 
(Intestinal infection) in the ICD-9-CM period also had the same phecodes in the ICD-10-
CM period (Table 2). 
  
  
Table 2. ICD-10-CM phecode map reproducibility analysis. 
Phenotype Phecodesa No. ICD-9-CM 
cases  
No. Individuals (%),  
(ICD-10-CM case | ICD-9-CM 
case)b 
Hypertension 401.* 65,216 49,468 (75.85%) 
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Hyperlipidemia 272.* 51,187 36,187 (70.70%) 
Type 1 diabetes 250.1* 5,782 4,412 (76.31%) 
Type 2 diabetes 250.2* 25,077 19,066 (76.03%) 
Intestinal 
infection 
008.* 3,410 273 (8.01%) 
  
aIn the phecode column, “*” means ≥1 digits or a period, e.g. phecode 401.* = phecodes 
401, 401.1, 401.3, 401.22, 401.21, 401.2. 
bIn the last column, “ICD-10-CM case | ICD-9-CM case” indicates patients who were 
cases for the phenotype of interest during the ICD-9-CM period who were also ICD-10-
CM cases.  
  
  
To identify the reasons that may explain why some patients were not identified as cases 
for the phenotype of interest during the ICD-10-CM period, we manually reviewed their 
medical records. Thirty patients were selected for review, ten each from the 
Hypertension, Hyperlipidemia, and Type 2 diabetes cohorts (Multimedia Appendix 1). 
We found that none of the patients had a relevant ICD-10-CM code for the phenotype 
being studied in the 18-month observation period. Reasons for patients not being ICD-
10-CM cases include: patients were labeled with the relevant ICD-10-CM code(s) 
outside of the short ICD-10-CM observation window (8 patients), patients had <2 visits 
at VUMC during the ICD-10-CM period and/or were only seen by physician specialists 
(10 patients; e.g. patient with hypertension was only seen by their neurologist during the 
ICD-10-CM period), and patients were inconsistently diagnosed (2 people; e.g. patient 
with Type 1 diabetes given Type 2 diabetes ICD-9-CM code). No cases were missed 
due to errors in the ICD-10-CM phecode map.  
  
Comparative PheWAS Analysis of LPA SNP, rs10455872 
To further evaluate the ICD-10-CM phecode map, we performed and compared the 
results of PheWAS analyses for rs10455872. One PheWAS was conducted using the 
ICD-9-CM map and another was conducted using the ICD-10-CM map. Both analyses 
replicated previous findings with similar effect sizes: coronary atherosclerosis (ICD-9-
CM: P=1.96E-15, odds ratio (OR) = 1.60, 95% confidence interval (CI): 1.43-1.80  vs. 
ICD-10-CM: P=8.63E-16, OR = 1.60, 95% CI: 1.43-1.80) and chronic ischemic heart 
disease (ICD-9-CM: P=4.18E-10, OR = 1.56, 95% CI: 1.35-1.79  vs. ICD-10-CM: 
P=5.21E-05, OR = 1.47, 95% CI: 1.22-1.77) (Figure 4). 
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Figure 4. Comparative PheWAS of lipoprotein(a) (LPA) genetic variant, rs10455872. 
“Coronary atherosclerosis” (phecode 411.4) and “Other chronic ischemic heart disease” 
(phecode 411.8) were top hits associated with rs10455872 in a PheWAS analysis 
conducted using ICD-9-CM (top) and ICD-10-CM (bottom) phecode maps. Analyses 
were adjusted for age, sex, and race. 
  
  
Discussion 
 
Main Findings: Maps of ICD-10 and ICD-10-CM Codes to Phecodes have High 
Coverage and Yield Similar Results as the ICD-9-CM Phecode Map.  
In this study, we described the process of mapping ICD-10 and ICD-10-CM codes to 
phecodes, and evaluated the results of the new maps in two databases. These results 
show that the majority of the ICD-10 and ICD-10-CM codes used in EHRs were mapped 
to phecodes. Our analyses suggest that researchers can expect that phenotypes 
sourced using the ICD-10-CM phecode map will be similar to those sourced from the 
gold-standard ICD-9-CM phecode map. As the use of ICD-10 and ICD-10-CM codes 
increases, so does the need for convenient and reliable methods of aggregating codes 
to represent clinically meaningful phenotypes.  
 
Since the introduction of phecodes, many studies have demonstrated the value of 
aggregating ICD-9-CM codes for genetic association studies. These maps will allow 
biomedical researchers to leverage clinical data represented by ICD-10 and ICD-10-CM 
codes for their large-scale PheWAS in the EHR. They will also allow researchers to 
combine phenotypes as phecodes mapped from ICD-9 and ICD-10 based coding 
systems, thereby increasing the size of their patient cohorts and statistical power of their 
studies. The maps are available from https://phewascatalog.org [33] and incorporated in 
the PheWAS R package, version 0.99.5 (https://github.com/PheWAS/PheWAS) 
[13,34].  
 
ICD-10 and ICD-10-CM Codes not Mapped to Phecodes    
Analysis of the unmapped ICD-10 codes demonstrates a possible area of expansion for 
phecodes. The ICD-10 phecode map did not include medical concepts representing 
personal history or family history of disease. 
 
We observed that a majority of the unmapped ICD-10-CM codes represented concepts 
that we did not expect to have phecode equivalents. Majority of the codes were from 
ICD-10-CM chapters 20 “External causes of morbidity” and 21 “Factors influencing 
health status and contact with health services”. Codes from chapter 19 “Injury, 
poisoning, and certain other consequences of external causes” also made up a large 
proportion of unmapped codes, such as ICD-10-CM T38.3X6A “Underdosing of insulin 
and oral hypoglycemic [antidiabetic] drugs, initial encounter”. We did not expect ICD-10-
CM T38.3X6A to map to a phecode, as it is an encounter code that is not relevant to 
PheWAS. Three-digit codes that are not frequently used for reimbursement purposes, 
such as ICD-10-CM I67 “Other cerebrovascular diseases”, also made up a large 
number of unmapped codes. A few potential clinically meaningful phenotypes, such as 
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ICD-10-CM O04.6 “Delayed or excessive hemorrhage following [induced] termination of 
pregnancy”, were unmapped and represent areas of potential expansion for phecodes. 
 
ICD-10-CM Phecode Map Phenotype Reproducibility Analysis   
In general, our analysis suggests that in the majority of the cases in which phenotypes 
are not reproduced in the ICD-10-CM observation period are not due to errors in the 
ICD-10-CM phecode map. This study’s reproducibility analysis (Table 2) demonstrates 
that the vast majority of patients (70-75%) with phecodes of four chronic diseases 
sourced from ICD-9-CM codes were also phenotype cases in the ICD-10-CM era. In 
comparison, when the same experiment is repeated for an acute disease (Intestinal 
infection), a minority (<10%) of patients had the same phenotype in the ICD-10-CM 
period.  
 
Using the ICD-9-CM and ICD-10-CM maps, PheWAS found significant genetic 
associations with similar effect sizes for coronary atherosclerosis and chronic ischemic 
heart disease (Figure 4). Results of this analysis provide additional support for the 
accuracy of the ICD-10-CM map when compared to the gold-standard ICD-9-CM 
phecode map.  
 
PheWAS Using ICD-10 Phecode Map 
Two published studies have used the ICD-10 phecode map to identify genotype-
phenotype associations using UKBB data. Zhou et al. used the map to demonstrate a 
method that adjusts for case-control imbalances in a large genome-wide PheWAS [35]. 
Li et al. used the same map to estimate the causal effects of elevated serum uric acid 
across the phenome [12]. 
 
Utilization of Phecodes Outside of PheWAS 
In addition to being employed for PheWAS, phecodes have been used to answer a 
range of questions in biomedicine. Phecodes have been used to identify features in 
radiographic images that are associated with disease phenotypes [36], and used in 
machine learning models to improve cardiovascular disease prediction [37]. In a recent 
study to understand public opinion about diseases, Huang et al. identified articles about 
diseases and mapped them to phecodes [38]. Motivated by the difficulties in 
automatically translating diagnosis codes in the EHR, Shi et al. used phecodes to map 
ICD-9-CM diagnosis codes from one health system to another [39]. Phecodes have also 
been applied to identify conditions for aggregation in “phenotype risk scores”, much as 
SNPs are aggregated as a genetic risk score, to identify Mendelian diseases and 
determine pathogenicity of genetic variants [40].  
  
Related Work 
The Clinical Classification Software (CCS) is another maintained system for aggregating 
ICD codes into clinically meaningful phenotypes. CCS was originally developed by the 
Agency for Healthcare Research and Quality (AHRQ) to cluster ICD-9-CM diagnosis 
and procedure codes to a smaller number of clinically meaningful categories [41]. CCS 
has been used for many purposes, such as to measure outcomes [42] and to predict 
future health care usage [43]. In a previous study, we showed that phecodes better 
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aligned with diseases mentioned in clinical practice and that are relevant to genomic 
studies, than CCS for ICD-9-CM (CCS9) codes [20]. We found that phecodes 
outperform CCS9 codes, in part because CCS9 was not as granular as phecodes. 
Since CCS for ICD-10-CM (CCS10) is of similar granularity as CCS9 (283 vs. 285 
disease groups) [44], we believe that the phecode map would likely still better represent 
clinically meaningful phenotypes in genetic research. 
 
Limitations 
This study has limitations. First, only 84.14% (1570/1866) of phecodes are mapped to at 
least one ICD-10 code. This may be due in part to the automated strategy that we used 
to map ICD-10 to ICD-9-CM. Second, the VUMC data are from a single site, thereby 
making it difficult to generalize the results of our accuracy studies (e.g. phenotype 
reproducibility analysis and LPA SNP PheWAS) to patient cohorts in other EHRs. Third, 
we have not yet manually reviewed all of the mappings in these “beta” phecode maps, 
and our assumptions that the manually-reviewed resources (e.g. NLM and OHDSI) are 
highly accurate could have affected the accuracy of the new phecode maps. For 
example, in the 2009 ICD-10-CM to ICD-9-CM GEMS, >90% of the mappings were 
“approximate” (i.e. non-equivalent) [15]. For this study’s purposes, we aimed to 
maximize phecode coverage of ICD source codes, and thus included both equivalent 
and non-equivalent 2018 GEMS translations, which could have decreased mapping 
performance.  
 
Fourth, our automated approach to map >80,000 ICD-10-CM and >9,000 ICD-10 codes 
to phecodes with minimal human-engineering could have decreased the accuracy of the 
final maps. Hripcsak et al. [45] recently evaluated the effects of translating ICD-9-CM 
codes to SNOMED CT codes on the creation of patient cohorts. In general, they found 
that mapping source billing codes to a standard clinical vocabulary (e.g. ICD-9-CM to 
SNOMED CT) did not greatly affect cohort selection. Their findings suggested that 
optimized domain knowledge-engineered mappings outperformed simple automated 
translations between clinical vocabularies. Using four phenotype concept sets, they 
showed that automated mappings resulted in errors of up to 10% and that domain-
knowledge engineered mappings to have errors of <.5%. Other studies have also found 
that mapping performance is generally better with smaller value sets [17]. To create a 
more comprehensive and accurate map between ICD-9-CM and ICD-10-CM, future 
mapping studies could consider using an iterative forward and backward mapping 
approach using GEMS [17].  
 
Future Directions 
Currently, if an ICD-10 or ICD-10-CM code maps to ≥2 codes unlinked phecodes, we 
keep all of the mappings. In subsequent studies, it will be important to further scrutinize 
these mappings to ensure accuracy through manual review. As new ICD-10-CM codes 
are released, we plan to assess their relevance to clinical practice and genetic research, 
and decide whether we should translate them to phecodes. We intend to address the 
unmapped source codes (e.g. ICD-10-CM E78.41 “Elevated Lipoprotein(a)”) by 
potentially expanding the phecode system, and to systematically evaluate the mappings 
with input from users.  
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Conclusions 
In this paper, we introduced our work on mapping ICD-10 and ICD-10-CM codes to 
phecodes. We provide initial “beta” maps with high coverage of EHR data in two large 
databases. Results from this study suggested that the ICD-10-CM phecode map 
created phenotypes similar to those generated by the ICD-9-CM phecode map. These 
mappings will enable researchers to leverage accumulated ICD-10 and ICD-10-CM data 
in the EHR for large PheWAS. 
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Multimedia Appendix 1: ICD-10-CM reproducibility analysis, manual chart review 
results 
Phenotype Group Number of People 
Hypertension absence of ICD-10-CM only 2 
Hyperlipidemia absence of ICD-10-CM only 4 
Type 2 diabetes absence of ICD-10-CM only 4 
Hypertension short observation window 1 
Hyperlipidemia short observation window 4 
Type 2 diabetes short observation window 3 
Hypertension limited number of visits/specialist 7 
Hyperlipidemia limited number of visits/specialist 2 
Type 2 diabetes limited number of visits/specialist 1 
Hypertension inconsistent diagnosis 0 
Hyperlipidemia inconsistent diagnosis 0 
Type 2 diabetes inconsistent diagnosis 2 
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